Drug Patents owned by Palatin Technologies

1. List of Vyleesi (autoinjector) drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6794489 PALATIN TECHNOLOGIES Compositions and methods for treatment of sexual dysfunction
Jun, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9352013 PALATIN TECHNOLOGIES Uses of bremelanotide in therapy for female sexual dysfunction
Nov, 2033

(10 years from now)

US9700592 PALATIN TECHNOLOGIES Uses of bremelanotide in therapy for female sexual dysfunction
Nov, 2033

(10 years from now)

US10286034 PALATIN TECHNOLOGIES Uses of bremelanotide in therapy for female sexual dysfunction
Nov, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 21, 2024

Drugs and Companies using BREMELANOTIDE ACETATE ingredient

NCE-1 date: June, 2023

Market Authorisation Date: 21 June, 2019

Treatment: Treatment of hypoactive sexual desire disorder (hsdd)

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic